File: Attachment THC News Release - May 29 2025.pdf

THC BIOMED INTL LTD. P.O. Box 20033 Towne Centre

Kelowna, B.C. V1Y 9H2 www.thcbiomed.com

THC BioMed Intl Ltd. to Sell Two Strata Units in Kelowna, B.C.

Vancouver, Canada May 29, 2025 - THC BioMed Intl Ltd. (CSE:THC) ("THC BioMed") or (the "Company") is pleased to announce that it has accepted offers for the purchase and sale of two of its strata units at its Acland Road location in Kelowna, B.C., to be completed on June 4, 2025.

The total purchase price for both units is $800,000. $26,250 is expected to be paid out in real estate commissions. The Company expects to use the remainder of the proceeds to pay for other expenses of the transaction, the mortgage payout, CRA, other creditors and general working capital.

The buyer is an Arm's-Length Party.

The Issuer will lease these units back from the Buyer, to continue its business operations therein.

About THC Biomed:

THC Biomed is a leading cannabis company dedicated to producing high-quality, diverse cannabis products. With a focus on innovation and consumer satisfaction, THC Biomed strives to meet the evolving needs of cannabis enthusiasts through continuous research, development, and product excellence.

For more information, contact:

John Miller, CEO THC BioMed Intl Ltd. T: 1-844-THCMEDS E: info@thcbiomed.com

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this release include that (a) the Company will complete the sale of the units, (b) the purchase price will be a total of $800,000, (c) the closing date will be June 4, 2025, (d) the real estate commissions will be the total stated above, (e) the Company will use the remainder of the proceeds as stated above, and (f) the Company will lease the units back from the Buyer. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

File: '\\swfile\EmailIn\20250529 163700 Attachment THC Press Release Sale of Strata Unit June 2025_May 29 2025.docx'

1414-6800-1815, v. 1

THC BIOMED INTL LTD.

P.O. Box 20033 Towne Centre

Kelowna, B.C. V1Y 9H2

www.thcbiomed.com

THC BioMed Intl Ltd. to Sell Two Strata Units in Kelowna, B.C.

Vancouver, Canada - May 29, 2025 - THC BioMed Intl Ltd. (CSE:THC) ("THC BioMed") or (the "Company") is pleased to announce that it has accepted offers for the purchase and sale of two of its strata units at its Acland Road location in Kelowna, B.C., to be completed on June 4, 2025.

The total purchase price for both units is $800,000. $26,250 is expected to be paid out in real estate commissions. The Company expects to use the remainder of the proceeds to pay for other expenses of the transaction, the mortgage payout, CRA, other creditors and general working capital.

The buyer is an Arm's-Length Party.

The Issuer will lease these units back from the Buyer, to continue its business operations therein.

About THC Biomed:

THC Biomed is a leading cannabis company dedicated to producing high-quality, diverse cannabis products. With a focus on innovation and consumer satisfaction, THC Biomed strives to meet the evolving needs of cannabis enthusiasts through continuous research, development, and product excellence.

For more information, contact:

John Miller, CEO

THC BioMed Intl Ltd.

T: 1-844-THCMEDS

E: info@thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this release include that (a) the Company will complete the sale of the units, (b) the purchase price will be a total of $800,000, (c) the closing date will be June 4, 2025, (d) the real estate commissions will be the total stated above, (e) the Company will use the remainder of the proceeds as stated above, and (f) the Company will lease the units back from the Buyer. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.